Сурфактантные протеины A и D в диагностике идиопатического легочного фиброза и саркоидоза
Сурфактантные протеины A и D в диагностике идиопатического легочного фиброза и саркоидоза
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представлены результаты клинического исследования, показавшего значение сурфактантных протеинов А и D в оценке активности и прогрессирования идиопатического легочного фиброза (ИЛФ) и хронического саркоидоза легких.
Цель. Изучить клиническое значение SP-A, SP-D в оценке активности ИЛФ и саркоидоза.
Материалы и методы. Обследован 81 пациент с морфологически подтвержденными диагнозами ИЛФ и саркоидоза, контрольная группа – 20 здоровых лиц. Выполняли мультиспиральную компьютерную томографию (МСКТ) ВР органов грудной клетки, исследовали диффузионную способность легких, определяли сатурацию кислорода. В сыворотке крови определяли сурфактантные протеины SP-A и SP-D методом иммуноферментного твердофазного анализа.
Результаты. По сравнению с пациентами контрольной группы у больных отмечали достоверное повышение SP-A и SP-D (p<0,05), выявили прямую корреляцию с признаками активности: SP-A с альвеолитом (p<0,05), SP-D с прогрессирующим фиброзом (p<0,05), обратную корреляцию сурфактантных протеинов с показателями респираторной функции (p<0,05).
Заключение. Серологические показатели SP-A и SP-D отражают активность альвеолита и прогрессирование легочного фиброза у больных с ИЛФ и саркоидозом.
Ключевые слова: саркоидоз, идиопатический легочный фиброз, сурфактантный протеин А, сурфактантный протеин D.
Aim. To study the clinical significance of SP-A, SP-D in assessing the activity of idiopathic pulmonary fibrosis and sarcoidosis.
We examined 81 patients with morphologically confirmed diagnoses of idiopathic pulmonary fibrosis (ILF) and sarcoidosis, a control group of 20 healthy individuals. The MSCT of the thoracic organs of the chest was performed, the diffusivity of the lungs was examined, oxygen saturation was determined. In the serum, the surfactant proteins SP-A and SP-D were determined by the enzyme-linked immunosorbent assay.
Results. A significant increase in SP-A and SP-D (p<0.05) was observed in patients compared with patients in the control group, a direct correlation was found with signs of activity: SP-A with alveolitis (p<0.05), SP- D with progressive fibrosis (p<0.05), inverse correlation of surfactant proteins with respiratory function indices (p<0.05).
Conclusion. Serological parameters of SP-A and SP-D reflect the activity of alveolitis and the progression of pulmonary fibrosis in patients with ILF and sarcoidosis.
Keywords: sarcoidosis, interstitial lung diseases, pulmonary fibrosis, surfactant protein A, surfactant protein D.
Цель. Изучить клиническое значение SP-A, SP-D в оценке активности ИЛФ и саркоидоза.
Материалы и методы. Обследован 81 пациент с морфологически подтвержденными диагнозами ИЛФ и саркоидоза, контрольная группа – 20 здоровых лиц. Выполняли мультиспиральную компьютерную томографию (МСКТ) ВР органов грудной клетки, исследовали диффузионную способность легких, определяли сатурацию кислорода. В сыворотке крови определяли сурфактантные протеины SP-A и SP-D методом иммуноферментного твердофазного анализа.
Результаты. По сравнению с пациентами контрольной группы у больных отмечали достоверное повышение SP-A и SP-D (p<0,05), выявили прямую корреляцию с признаками активности: SP-A с альвеолитом (p<0,05), SP-D с прогрессирующим фиброзом (p<0,05), обратную корреляцию сурфактантных протеинов с показателями респираторной функции (p<0,05).
Заключение. Серологические показатели SP-A и SP-D отражают активность альвеолита и прогрессирование легочного фиброза у больных с ИЛФ и саркоидозом.
Ключевые слова: саркоидоз, идиопатический легочный фиброз, сурфактантный протеин А, сурфактантный протеин D.
________________________________________________
Aim. To study the clinical significance of SP-A, SP-D in assessing the activity of idiopathic pulmonary fibrosis and sarcoidosis.
We examined 81 patients with morphologically confirmed diagnoses of idiopathic pulmonary fibrosis (ILF) and sarcoidosis, a control group of 20 healthy individuals. The MSCT of the thoracic organs of the chest was performed, the diffusivity of the lungs was examined, oxygen saturation was determined. In the serum, the surfactant proteins SP-A and SP-D were determined by the enzyme-linked immunosorbent assay.
Results. A significant increase in SP-A and SP-D (p<0.05) was observed in patients compared with patients in the control group, a direct correlation was found with signs of activity: SP-A with alveolitis (p<0.05), SP- D with progressive fibrosis (p<0.05), inverse correlation of surfactant proteins with respiratory function indices (p<0.05).
Conclusion. Serological parameters of SP-A and SP-D reflect the activity of alveolitis and the progression of pulmonary fibrosis in patients with ILF and sarcoidosis.
Keywords: sarcoidosis, interstitial lung diseases, pulmonary fibrosis, surfactant protein A, surfactant protein D.
Список литературы
1. Интерстициальные болезни легких./ Под ред. Н.А. Мухина. М.: Литтерра. 2007; 434 с. [Interstitial lung disease./ Ed. Mukhina. M.: Litterra. 2007; 434 p. (In Russ.)]
2. Мухин Н., Корнев Б., Попова Е. и др. Саркоидоз прогрессирующего течения. Врач. 2003; (8): 20-27. [Mukhin N, Kornev B, Popova E et al. Sarcoidosis of progressive course. Doctor. 2003; (8): 20-27. (In Russ.)]
3. Baugman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015 Oct;3(10):813-22. doi: 10.1016/ S2213-2600(15)00199-X.
4. Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология. 2015;25(5):600-612. doi:10.18093/0869-0189-2015-25-5-600–612. / Аvdeev S. N. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25 (5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612.
5. Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Часть 2. Consilium Medicum. Болезни органов дыхания. (Прил.). 2014; 01: 7-9. [Ilkovich MM. Interstitial lung disease: reasoning on the actual topic. Part 2. Consilium Medicum. Diseases of the respiratory system. (ADJ.). 2014; 01: 7-9. (In Russ.)]
6. Мухин H.A., Серов В.В., Коган Е.А. и др. Клинико-морфологическая характеристика интерстициальных болезней легких. Клин медицина. 1995; (3): 77-80. [Mukhin HA, Serov VV, Kogan EA et al. Clinical and morphological characteristics of interstitial lung diseases. Wedge medicine. 1995; (3): 77-80. (In Russ.)]
7. Raghu G, Lynch D, Godwin JD et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6.
8. Микеров А.Н. Роль сурфактантного белка А в иммунной защите легких. Фундаментальные исследования. 2012; (2): 204-207. [Mikerov AN. The role of surfactant protein a in the immune defense of the lungs. Fundamental study. 2012; (2): 204-207. (In Russ.)]
9. Greene KE, King TE Jr, Kuroki Y et al. Serum surfactant proteins-A and –D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439-46.
10. Ishikawa T, Kubota T, Abe H et al. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868
11. Nakamura K, Kato M, Shukuya T et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.
12. Чучалин А.Г., Визель А.А., Илькович М.М. и др. Диагностика и лечение саркоидоза: резюме федеральных согласительных клинических рекомендаций (Часть II. Диагностика, лечение, прогноз). Вестник современной клинической медицины. 2014; 7 (выпуск 5): 73–81. [Chuchalin AG, Vizel AA, Ilkovich MM et al. Diagnosis and treatment of sarcoidosis: summary of Federal conciliation clinical recommendations (Part II. Diagnosis, treatment, prognosis). Herald of modern clinical medicine. 2014; 7 (issue 5): 73–81. (In Russ.)]
13. Идиопатический легочный фиброз. Клинические рекомендации Минздрава РФ, 2016: 44 c. [Idiopathic pulmonary fibrosis. Clinical practice guidelines, Ministry of health of the Russian Federation, 2016: 44 c. (In Russ.)]
14. Launois C, Barbe C, Bertin E et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study BMC Pulmonary Medicine. 2012; 12:61. doi: 10.1186/ 1471-2466-12-61.
15. Программа «STATISTICA Advanced”. Описание. http://statsoft.ru/ products/STATISTICA_Advanced/ актуально на 25.07.2017. [The program "STATISTICA Advanced". Description. http://statsoft.ru/ products/STATISTICA_Advanced/ relevant to the 25.07.2017. (In Russ.)]
16. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. Практическое руководство. М.: ГЭОТАР- Медиа, 2006; 304. [Sergienko VI, Bondareva IB. Mathematical statistics in clinical research. Practical guide. M.: GEOTAR-Media, 2006; 304. (In Russ.)]
17. Chernecky CC. Laboratory tests and diagnostic procedures / CC. Chernecky, BJ. Berger; 5th ed. – Saunder Elsevier, 2008. – 1232 pp.
18. Hara Y, Shinkai M, Kanoh S et al. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Intern Med. 2017;56(6):621-626. doi: 10.2169/internalmedicine.56.7418.
19. Лапин С.В., Тотолян А.А. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. СПб.: Человек, 2010. – с. 272. [Lapin SV, Totolyan AA. The Immunological laboratory diagnostics of autoimmune diseases. SPb.: Man, 2010. - p. 272. (In Russ.)]
20. Волель Б., Макух Е., Лебедева М. и др. Клинико-лабораторные маркеры астенического синдрома у больных саркоидозом. Врач. 2016;( 7): 74–76. [Volel B, Makukh E, Lebedeva M et al. Clinical and laboratory markers of asthenic syndrome in patients with sarcoidosis. Doctor. 2016; (7): 74–76. (In Russ.)]
21. Spagnolo P, Sverzellati N, Rossi G. IPF in 2016: towards a better diagnosis. Lancet Respir Med. 2016 Dec;4(12):945-947. doi: 10.1016/ S2213-2600(16)30375-7.
22. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5 (1):72-84. doi: 10.1016/S2213-2600(16)30222-3.
23. Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017.
2. [Mukhin N, Kornev B, Popova E et al. Sarcoidosis of progressive course. Doctor. 2003; (8): 20-27. (In Russ.)]
3. Baugman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015 Oct;3(10):813-22. doi: 10.1016/ S2213-2600(15)00199-X.
4. Аvdeev S. N. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25 (5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612.
5. [Ilkovich MM. Interstitial lung disease: reasoning on the actual topic. Part 2. Consilium Medicum. Diseases of the respiratory system. (ADJ.). 2014; 01: 7-9. (In Russ.)]
6. [Mukhin HA, Serov VV, Kogan EA et al. Clinical and morphological characteristics of interstitial lung diseases. Wedge medicine. 1995; (3): 77-80. (In Russ.)]
7. Raghu G, Lynch D, Godwin JD et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6.
8. [Mikerov AN. The role of surfactant protein a in the immune defense of the lungs. Fundamental study. 2012; (2): 204-207. (In Russ.)]
9. Greene KE, King TE Jr, Kuroki Y et al. Serum surfactant proteins-A and –D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439-46.
10. Ishikawa T, Kubota T, Abe H et al. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868
11. Nakamura K, Kato M, Shukuya T et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.
12. [Chuchalin AG, Vizel AA, Ilkovich MM et al. Diagnosis and treatment of sarcoidosis: summary of Federal conciliation clinical recommendations (Part II. Diagnosis, treatment, prognosis). Herald of modern clinical medicine. 2014; 7 (issue 5): 73–81. (In Russ.)]
13. [Idiopathic pulmonary fibrosis. Clinical practice guidelines, Ministry of health of the Russian Federation, 2016: 44 c. (In Russ.)]
14. Launois C, Barbe C, Bertin E et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study BMC Pulmonary Medicine. 2012; 12:61. doi: 10.1186/ 1471-2466-12-61.
15. [The program "STATISTICA Advanced". Description. http://statsoft.ru/ products/STATISTICA_Advanced/ relevant to the 25.07.2017. (In Russ.)]
16. [Sergienko VI, Bondareva IB. Mathematical statistics in clinical research. Practical guide. M.: GEOTAR-Media, 2006; 304. (In Russ.)]
17. Chernecky CC. Laboratory tests and diagnostic procedures / CC. Chernecky, BJ. Berger; 5th ed. – Saunder Elsevier, 2008. – 1232 pp.
18. Hara Y, Shinkai M, Kanoh S et al. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Intern Med. 2017;56(6):621-626. doi: 10.2169/internalmedicine.56.7418.
19. [Lapin SV, Totolyan AA. The Immunological laboratory diagnostics of autoimmune diseases. SPb.: Man, 2010. - p. 272. (In Russ.)]
20. [Volel B, Makukh E, Lebedeva M et al. Clinical and laboratory markers of asthenic syndrome in patients with sarcoidosis. Doctor. 2016; (7): 74–76. (In Russ.)]
21. Spagnolo P, Sverzellati N, Rossi G. IPF in 2016: towards a better diagnosis. Lancet Respir Med. 2016 Dec;4(12):945-947. doi: 10.1016/ S2213-2600(16)30375-7.
22. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5 (1):72-84. doi: 10.1016/S2213-2600(16)30222-3.
23. Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017.
2. Мухин Н., Корнев Б., Попова Е. и др. Саркоидоз прогрессирующего течения. Врач. 2003; (8): 20-27. [Mukhin N, Kornev B, Popova E et al. Sarcoidosis of progressive course. Doctor. 2003; (8): 20-27. (In Russ.)]
3. Baugman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015 Oct;3(10):813-22. doi: 10.1016/ S2213-2600(15)00199-X.
4. Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология. 2015;25(5):600-612. doi:10.18093/0869-0189-2015-25-5-600–612. / Аvdeev S. N. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25 (5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612.
5. Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Часть 2. Consilium Medicum. Болезни органов дыхания. (Прил.). 2014; 01: 7-9. [Ilkovich MM. Interstitial lung disease: reasoning on the actual topic. Part 2. Consilium Medicum. Diseases of the respiratory system. (ADJ.). 2014; 01: 7-9. (In Russ.)]
6. Мухин H.A., Серов В.В., Коган Е.А. и др. Клинико-морфологическая характеристика интерстициальных болезней легких. Клин медицина. 1995; (3): 77-80. [Mukhin HA, Serov VV, Kogan EA et al. Clinical and morphological characteristics of interstitial lung diseases. Wedge medicine. 1995; (3): 77-80. (In Russ.)]
7. Raghu G, Lynch D, Godwin JD et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6.
8. Микеров А.Н. Роль сурфактантного белка А в иммунной защите легких. Фундаментальные исследования. 2012; (2): 204-207. [Mikerov AN. The role of surfactant protein a in the immune defense of the lungs. Fundamental study. 2012; (2): 204-207. (In Russ.)]
9. Greene KE, King TE Jr, Kuroki Y et al. Serum surfactant proteins-A and –D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439-46.
10. Ishikawa T, Kubota T, Abe H et al. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868
11. Nakamura K, Kato M, Shukuya T et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.
12. Чучалин А.Г., Визель А.А., Илькович М.М. и др. Диагностика и лечение саркоидоза: резюме федеральных согласительных клинических рекомендаций (Часть II. Диагностика, лечение, прогноз). Вестник современной клинической медицины. 2014; 7 (выпуск 5): 73–81. [Chuchalin AG, Vizel AA, Ilkovich MM et al. Diagnosis and treatment of sarcoidosis: summary of Federal conciliation clinical recommendations (Part II. Diagnosis, treatment, prognosis). Herald of modern clinical medicine. 2014; 7 (issue 5): 73–81. (In Russ.)]
13. Идиопатический легочный фиброз. Клинические рекомендации Минздрава РФ, 2016: 44 c. [Idiopathic pulmonary fibrosis. Clinical practice guidelines, Ministry of health of the Russian Federation, 2016: 44 c. (In Russ.)]
14. Launois C, Barbe C, Bertin E et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study BMC Pulmonary Medicine. 2012; 12:61. doi: 10.1186/ 1471-2466-12-61.
15. Программа «STATISTICA Advanced”. Описание. http://statsoft.ru/ products/STATISTICA_Advanced/ актуально на 25.07.2017. [The program "STATISTICA Advanced". Description. http://statsoft.ru/ products/STATISTICA_Advanced/ relevant to the 25.07.2017. (In Russ.)]
16. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. Практическое руководство. М.: ГЭОТАР- Медиа, 2006; 304. [Sergienko VI, Bondareva IB. Mathematical statistics in clinical research. Practical guide. M.: GEOTAR-Media, 2006; 304. (In Russ.)]
17. Chernecky CC. Laboratory tests and diagnostic procedures / CC. Chernecky, BJ. Berger; 5th ed. – Saunder Elsevier, 2008. – 1232 pp.
18. Hara Y, Shinkai M, Kanoh S et al. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Intern Med. 2017;56(6):621-626. doi: 10.2169/internalmedicine.56.7418.
19. Лапин С.В., Тотолян А.А. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. СПб.: Человек, 2010. – с. 272. [Lapin SV, Totolyan AA. The Immunological laboratory diagnostics of autoimmune diseases. SPb.: Man, 2010. - p. 272. (In Russ.)]
20. Волель Б., Макух Е., Лебедева М. и др. Клинико-лабораторные маркеры астенического синдрома у больных саркоидозом. Врач. 2016;( 7): 74–76. [Volel B, Makukh E, Lebedeva M et al. Clinical and laboratory markers of asthenic syndrome in patients with sarcoidosis. Doctor. 2016; (7): 74–76. (In Russ.)]
21. Spagnolo P, Sverzellati N, Rossi G. IPF in 2016: towards a better diagnosis. Lancet Respir Med. 2016 Dec;4(12):945-947. doi: 10.1016/ S2213-2600(16)30375-7.
22. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5 (1):72-84. doi: 10.1016/S2213-2600(16)30222-3.
23. Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017.
________________________________________________
2. [Mukhin N, Kornev B, Popova E et al. Sarcoidosis of progressive course. Doctor. 2003; (8): 20-27. (In Russ.)]
3. Baugman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015 Oct;3(10):813-22. doi: 10.1016/ S2213-2600(15)00199-X.
4. Аvdeev S. N. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25 (5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612.
5. [Ilkovich MM. Interstitial lung disease: reasoning on the actual topic. Part 2. Consilium Medicum. Diseases of the respiratory system. (ADJ.). 2014; 01: 7-9. (In Russ.)]
6. [Mukhin HA, Serov VV, Kogan EA et al. Clinical and morphological characteristics of interstitial lung diseases. Wedge medicine. 1995; (3): 77-80. (In Russ.)]
7. Raghu G, Lynch D, Godwin JD et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6.
8. [Mikerov AN. The role of surfactant protein a in the immune defense of the lungs. Fundamental study. 2012; (2): 204-207. (In Russ.)]
9. Greene KE, King TE Jr, Kuroki Y et al. Serum surfactant proteins-A and –D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439-46.
10. Ishikawa T, Kubota T, Abe H et al. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868
11. Nakamura K, Kato M, Shukuya T et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.
12. [Chuchalin AG, Vizel AA, Ilkovich MM et al. Diagnosis and treatment of sarcoidosis: summary of Federal conciliation clinical recommendations (Part II. Diagnosis, treatment, prognosis). Herald of modern clinical medicine. 2014; 7 (issue 5): 73–81. (In Russ.)]
13. [Idiopathic pulmonary fibrosis. Clinical practice guidelines, Ministry of health of the Russian Federation, 2016: 44 c. (In Russ.)]
14. Launois C, Barbe C, Bertin E et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study BMC Pulmonary Medicine. 2012; 12:61. doi: 10.1186/ 1471-2466-12-61.
15. [The program "STATISTICA Advanced". Description. http://statsoft.ru/ products/STATISTICA_Advanced/ relevant to the 25.07.2017. (In Russ.)]
16. [Sergienko VI, Bondareva IB. Mathematical statistics in clinical research. Practical guide. M.: GEOTAR-Media, 2006; 304. (In Russ.)]
17. Chernecky CC. Laboratory tests and diagnostic procedures / CC. Chernecky, BJ. Berger; 5th ed. – Saunder Elsevier, 2008. – 1232 pp.
18. Hara Y, Shinkai M, Kanoh S et al. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Intern Med. 2017;56(6):621-626. doi: 10.2169/internalmedicine.56.7418.
19. [Lapin SV, Totolyan AA. The Immunological laboratory diagnostics of autoimmune diseases. SPb.: Man, 2010. - p. 272. (In Russ.)]
20. [Volel B, Makukh E, Lebedeva M et al. Clinical and laboratory markers of asthenic syndrome in patients with sarcoidosis. Doctor. 2016; (7): 74–76. (In Russ.)]
21. Spagnolo P, Sverzellati N, Rossi G. IPF in 2016: towards a better diagnosis. Lancet Respir Med. 2016 Dec;4(12):945-947. doi: 10.1016/ S2213-2600(16)30375-7.
22. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5 (1):72-84. doi: 10.1016/S2213-2600(16)30222-3.
23. Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017.
Авторы
В.Д. БЕКЕТОВ 1, М.В. ЛЕБЕДЕВА 2, Н.А. МУХИН 1,2 , А.Г. СЕРОВА 2, А.Б. ПОНОМАРЕВ 2, Е.Н. ПОПОВА 2, А.Ш. ЯНАКАЕВА 2, В.А. СОЛОМКА 2, А.В. КОНДРАШОВ 2, Д.В. КОНОВАЛОВ 2
1 ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова», Москва, Россия;
2 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва, Россия
1 Lomonosov Moscow State University, Moscow, Russia;
2 Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University, Moscow, Russia
1 ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова», Москва, Россия;
2 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва, Россия
________________________________________________
1 Lomonosov Moscow State University, Moscow, Russia;
2 Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.